Abstract P4-02-13: Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials

MLA

Gaia Griguolo, et al. “Abstract P4-02-13: Homologous Recombination Deficiency, RB-Loss Gene Signatures, Intrinsic Subtype and Response to Neoadjuvant Treatment in HR+/HER2- Early Breast Cancer: A Correlative Analysis of Two Phase II Trials.” Cancer Research, vol. 83, Mar. 2023, pp. P4-02. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs22-p4-02-13.

APA

Gaia Griguolo, Federica Miglietta, Laia Paré, Daniele G. Generali, Antonio Frassoldati, Antonino Musolino, Simon Spazzapan, Grazia Vernaci, Tommaso Giarratano, Marcello Lo Mele, Giancarlo Bisagni, Federico Piacentini, Enrico Tagliafico, Katia Cagossi, Francesca Schiavi, Claudia Pinato, Aleix Prat, Valentina Guarneri, & Maria Vittoria Dieci. (2023). Abstract P4-02-13: Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials. Cancer Research, 83, P4-02. https://doi.org/10.1158/1538-7445.sabcs22-p4-02-13

Chicago

Gaia Griguolo, Federica Miglietta, Laia Paré, Daniele G. Generali, Antonio Frassoldati, Antonino Musolino, Simon Spazzapan, et al. 2023. “Abstract P4-02-13: Homologous Recombination Deficiency, RB-Loss Gene Signatures, Intrinsic Subtype and Response to Neoadjuvant Treatment in HR+/HER2- Early Breast Cancer: A Correlative Analysis of Two Phase II Trials.” Cancer Research 83 (March): P4-02. doi:10.1158/1538-7445.sabcs22-p4-02-13.